ImmuCell Corporation

NasdaqCM ICCC

ImmuCell Corporation Price to Sales Ratio (P/S) on February 06, 2025

ImmuCell Corporation Price to Sales Ratio (P/S) is NA on February 06, 2025, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • ImmuCell Corporation 52-week high Price to Sales Ratio (P/S) is 2.64 on March 04, 2024, which is NA below the current Price to Sales Ratio (P/S).
  • ImmuCell Corporation 52-week low Price to Sales Ratio (P/S) is 1.30 on September 24, 2024, which is NA below the current Price to Sales Ratio (P/S).
  • ImmuCell Corporation average Price to Sales Ratio (P/S) for the last 52 weeks is 1.85.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Loading...
SV Wall Street
NasdaqCM: ICCC

ImmuCell Corporation

CEO Mr. Michael F. Brigham
IPO Date May 5, 1987
Location United States
Headquarters 56 Evergreen Drive
Employees 75
Sector Consumers Staples
Industries
Description

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Similar companies

MNOV

MediciNova, Inc.

USD 1.92

0.52%

LIPO

Lipella Pharmaceuticals Inc.

USD 4.65

80.23%

RZLT

Rezolute, Inc.

USD 5.12

-8.08%

CVKD

Cadrenal Therapeutics, Inc. Common Stock

USD 19.10

-3.29%

FENC

Fennec Pharmaceuticals Inc.

USD 6.66

-1.92%

ANEB

Anebulo Pharmaceuticals, Inc.

USD 1.54

-1.91%

StockViz Staff

February 7, 2025

Any question? Send us an email